Cerus Corporation to Release Fourth Quarter and Year End 2007 Financial Results on Thursday, February 21, 2008

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end 2007 financial results will be released on Thursday, February 21, 2008 after the close of the market and that it will host a conference call and live webcast at 4:30 p.m. EST that afternoon. Management will discuss the companys fourth quarter and year end 2007 results and provide an overview of the company.

To access the webcast via the internet, log on to www.cerus.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software downloads. Alternatively, you may access the live conference call by dialing 877-407-0782 (U.S.) or 201-689-8567 (International). A telephone replay will be available approximately two hours after the call through 11:59 p.m. EST, February 28, 2008. To access the replay, please call 877-660-6853 (U.S.) or 201-612-7415 (International) and enter account number 286 and conference ID number 274491. The webcast will be archived on www.cerus.com through March 21, 2008.


Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.


Cerus Corporation
William J. Dawson, 925-288-6053
Vice President, Finance & CFO
Vida Communication (On behalf of CERUS)
Stephanie Diaz, 415-675-7402

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.